GMTX Stock Forecast 2025-2026
Distance to GMTX Price Targets
GMTX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Gemini (GMTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on GMTX and similar high-potential opportunities.
Latest GMTX Stock Price Targets & Analyst Predictions
GMTX has shown a year-to-date change of -15.9% and a 1-year change of -13.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for GMTX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GMTX Analyst Ratings
GMTX Price Target Range
Latest GMTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GMTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2022 | HC Wainwright & Co. | Andrew Fein | Neutral | Downgrade | $2.00 |
| Mar 3, 2022 | SVB Leerink | Marc Goodman | Market Perform | Downgrade | $2.00 |
| Mar 1, 2022 | Jefferies | Chris Howerton | Hold | Downgrade | $1.50 |
| Jan 24, 2022 | SVB Leerink | Outperform | Maintains | $10.00 | |
| Dec 20, 2021 | SVB Leerink | Marc Goodman | Outperform | Maintains | $15.00 |
| Dec 15, 2021 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Oct 6, 2021 | Goldman Sachs | Graig Suvannavejh | Buy | Maintains | $18.00 |
| Apr 8, 2021 | SVB Leerink | Outperform | Initiates | $0.00 | |
| Mar 3, 2021 | Jefferies | Buy | Initiates | $0.00 | |
| Mar 2, 2021 | Goldman Sachs | Buy | Initiates | $0.00 |
Gemini Therapeutics, Inc. (GMTX) Competitors
The following stocks are similar to Gemini based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Gemini Therapeutics, Inc. (GMTX) Financial Data
Gemini Therapeutics, Inc. has a market capitalization of $420.69M with a P/E ratio of -11.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +38.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Gemini Therapeutics, Inc. (GMTX) Business Model
About Gemini Therapeutics, Inc.
Company Information
Sector
Industry
Employees
0
CEO
Country
United States
IPO Year
2020
Website
www.geminitherapeutics.comGemini Therapeutics, Inc. (GMTX) Latest News & Analysis
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation
2 years agoBronstein, Gewirtz & Grossman, LLC is investigating potential claims for FS Development Corp. investors post-merger with Gemini Therapeutics (NASDAQ: GMTX) on February 5, 2021.
The investigation into FS Development Corp. and Gemini Therapeutics may indicate potential legal issues, affecting stock performance and investor sentiment regarding $GMTX.
Disc Medicine, Inc. received FDA Orphan Drug Designation for bitopertin, aimed at treating erythropoietic protoporphyria (EPP), enhancing its development prospects in hematologic diseases.
The FDA's Orphan Drug Designation for bitopertin enhances Disc Medicine's market potential, potentially leading to increased funding, partnerships, and investor confidence in its future growth.
Short-squeeze stocks gained popularity as investors bet against bearish traders, creating a competitive dynamic in the market.
Short-squeeze stocks can lead to rapid price increases, creating volatility and potential profit opportunities for investors betting against bearish sentiment.
Disc Medicine has launched the AURORA Phase 2 study to evaluate bitopertin for treating adults with erythropoietic protoporphyria (EPP). Top-line data is expected in 2023.
The AURORA study's results could significantly impact Disc Medicine's stock value, influencing investor sentiment based on the potential success of bitopertin in treating EPP.
Halper Sadeh LLC is investigating Gemini Therapeutics, Inc. (NASDAQ: GMTX) for potential securities law violations related to its merger with Disc Medicine, Inc., with pre-merger shareholders owning 28% of the new entity.
The investigation into Gemini Therapeutics' merger may indicate potential legal issues, affecting shareholder value and investor confidence in the merged entity.
Halper Sadeh LLP is investigating Seacoast Banking Corporation's merger with Professional Holding Corp. for potential securities law violations and fiduciary duty breaches.
The investigation into Seacoast Banking's merger may indicate potential legal issues, impacting stock performance and shareholder rights, which could influence investment decisions and valuations.
Frequently Asked Questions About GMTX Stock
What is Gemini Therapeutics, Inc.'s (GMTX) stock forecast for 2025?
Analyst forecasts for Gemini Therapeutics, Inc. (GMTX) are not currently available. The stock is trading at $52.49.
Is GMTX stock a good investment in 2025?
Analyst ratings for GMTX are not currently available. The stock is currently trading at $52.49. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GMTX stock?
Price predictions from Wall Street analysts for GMTX are not currently available. The stock is trading at $52.49.
What is Gemini Therapeutics, Inc.'s business model?
N/A
What is the highest forecasted price for GMTX Gemini Therapeutics, Inc.?
Price targets from Wall Street analysts for GMTX are not currently available. The stock is trading at $52.49.
What is the lowest forecasted price for GMTX Gemini Therapeutics, Inc.?
Price targets from Wall Street analysts for GMTX are not currently available. The stock is trading at $52.49.
What is the overall GMTX consensus from analysts for Gemini Therapeutics, Inc.?
Analyst ratings for GMTX are not currently available. The stock is trading at $52.49.
How accurate are GMTX stock price projections?
Stock price projections, including those for Gemini Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
